Efficacy of risankizumab across subgroups in patients with active psoriatic arthritis: a post hoc integrated analysis of the phase 3 KEEPsAKE 1 and KEEPsAKE 2 randomized controlled trials

By sjmartinez • April 18, 2024

Merola JF, Armstrong A, Khattri S, Paek SY, Padilla B, Yue C, Photowala H, Kaplan B, Kristensen LE. Efficacy of risankizumab across subgroups in patients with active psoriatic arthritis: a post hoc integrated analysis of the phase 3 KEEPsAKE 1 and KEEPsAKE 2 randomized controlled trials. J Dermatolog Treat. 2024 Dec;35(1):2342383. doi: 10.1080/09546634.2024.2342383. Epub 2024 Apr 18. PMID: 38632977.

Tags: Biologics, Dermatology, interleukin-23, psoriatic arthritis, Publications, risankizumab

A New Twist on the Surgeon’s Knot: Quantifying Suture Security

Modiri O, Ebriani J, Sauvageau A, Davis J. A New Twist on the Surgeon's Knot: Quantifying Suture Security. Dermatol Surg. 2024 Nov 6. doi: 10.1097/DSS.0000000000004493.[...]

Long-Term Efficacy and Safety of Bimekizumab and Other Biologics in Moderate to Severe Plaque Psoriasis: Updated Systematic Literature Review and Network Meta-analysis

Warren RB, Donnelly K, Kiri S, Taieb V, Slim M, Fahrbach K, Neupane B, Betts M, Armstrong A. Long-Term Efficacy and Safety of Bimekizumab and[...]

Extracellular vesicles from human breast cancer-resistant cells promote acquired drug resistance and pro-inflammatory macrophage response

Santos P, Rezende CP, Piraine R, Oliveira B, Ferreira FB, Carvalho VS, Calado RT, Pellegrini M, Almeida F. Extracellular vesicles from human breast cancer-resistant cells[...]